|
celebrex news cases. Click here to read the FDA news release.On December 17th celebrex news, 2004 the National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI). The study celebrex news, called the Adenoma Prevention with Celecoxib (APC) trial celebrex news, was stopped because analysis by an independent Data Safety and Monitoring Board (DSMB) showed a 2.5-fold increased risk of major fatal and non-fatal cardiovascular events for participants taking the drug compared to those on a placebo.In the APC clinical trial celebrex news, patients taking 40 celebrex news.
celebrex news 0 mg. of Celebrex twice daily had a 3.4 times greater risk of cardiovascular events compared to placebo. For patients in the trial taking 200 mg. of Celebrex twice daily celebrex news, the risk was 2.5 times greater. The average duration of treatment in the trial was 33 months. However celebrex news, a similar ongoing study comparing Celebrex 400 mg. once a day versus placebo celebrex news, in patients followed for a similar period of time celebrex news, has not shown increased risk.Both the manufacturer of Celebrex (Pfizer) and the FDA are currently evaluating the data from these studies.Also on December 17 celebrex news, the FDA asked Pfizer celebrex news, Inc. to voluntarily suspend direct-to-consumer advertising on Celebrex during the time the FDA is obtaining and evaluating the new and conflicting scientific data on adverse events associated with the drug. FDA also requested Pfizer change the information provided to physicians to reflect the recommendations FDA made encouraging physicians to consider alternative therapies as they evaluate their individual patient needs. Pfizer agreed to suspend its Celebrex promotion and to craft appropriate detailing to physicians that reflects the uncertainty of scientific data currently available. You can read more about the above news items at:NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial (NIH) FDA Statement on the Halting of a Clin.
celebrex news Me the FDA is obtaining and evaluating the new and conflicting scientific data on adverse events associated with the drug. FDA also requested Pfizer change the information provided to physicians to reflect the recommendations FDA made encouraging physicians to consider alternative therapies as they evaluate their individual patient needs. Pfizer agreed to suspend its Celebrex promotion and to craft appropriate detailing to physicians that reflects the uncertainty of scientific data currently available. You can read more about the above news items at:NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial (NIH) FDA Statement on the Halting of a Clini.
celebrex news 
celebrex news | | | | | |
celebrex news
|
